Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23726781 | 0.94 | HPGD (0.43) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL21645085 | 0.91 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL13993955 | 0.91 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL21661371 | 0.91 | USP2 (0.41) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL10172533 | 0.87 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL18693034 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL321594 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL31726226 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL15368794 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2TACR1 | |
| SCHEMBL18418212 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111303014-A | Preparation method of 4- (aminomethyl) -4-fluoropiperidine-1-carboxylic acid tert-butyl ester | 山东药石药业有限公司 | 2020-06-19 | — | — | CN | claimed |
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| CN-116217566-B | Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025096858-A1 | COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2025-01-30 | — | — | US | disclosed |
| CN-114478520-B | Bcl-2 protein apoptosis inducer and application thereof | 杭州和正医药有限公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2011128455-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS | AC IMMUNE S.A. (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| EP-1901746-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | Merck & Co., Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002884-A2 | 4-FLUORO-PIPERIDINE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L2, BCL2L1 | USP2 1857/4885SMN1; SMN2 1747/4885HPGD 2926/4885 |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | BCL9L, BCL2L1, BCL2L2 | USP2 2710/4885SMN1; SMN2 1791/4885HPGD 1574/4885 |
| US-20100216841-A1 | 4-Fluoro-Piperidine T-Type Calcium Channel Antagonists | CACNA1G, CACNA1I, CACNA1H | USP2 4117/4885SMN1; SMN2 2069/4885HPGD 2720/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | USP2 1951/4885SMN1; SMN2 4687/4885HPGD 2313/4885 |
| US-20250034135-A1 | ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF | BCL2, BAX, BCL2L1 | USP2 908/4885SMN1; SMN2 2094/4885HPGD 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.